STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...

MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients.

- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System Savara Inc. (Nasdaq: SVRA) (the Company), a clinical ...

MONTEREY, Calif., Nov. 10 PARI Pharma GmbH hassuccessfully completed Phase I and Phase II clinical trials comparing itsproprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via ...

STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization of the LAMIRA ...

As highlighted in the April issue of Medical Device & Diagnostic Industry magazine, PARI Aerosol Research Institute has been awarded a 2006 Medical Design Excellence Award for eFlow. eFlow is an ...

MONTEREY, Calif., Nov. 26 PARI Pharma's eFlow electronicnebulizer was included in Gilead's (Nasdaq: GILD) recent New Drug Application(NDA) submittal to the U.S. Food and Drug Administration (FDA) for ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) ...

Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological ...